{{Use mdy dates|date=August 2015}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477215941
| IUPAC_name = 2-(4-bromo-2,5-dimethoxyphenyl)-''N''-[(2-methoxyphenyl)methyl]ethanamine
| image = 2C-B-NBOMe-skeletal.svg

<!--Clinical data-->
| tradename =
| legal_UK = Class A
| legal_US =Schedule I
| legal_DE = Anlage I

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1026511-90-9

| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = S6NAA81PHK

| PubChem = 9977044
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8152636

<!--Chemical data-->
| C=18 | H=22 | Br=1 | N=1 | O=3 
| molecular_weight = 380.275 g/mol
| smiles = COC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC)Br)OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H22BrNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SUXGNJVVBGJEFB-UHFFFAOYSA-N
}}
'''25B-NBOMe''' ('''NBOMe-2C-B''', '''Cimbi-36''', '''Nova''', '''BOM 2-CB''') is a derivative of the [[phenethylamine]] [[psychedelic drug|psychedelic]] [[2C-B]], discovered in 2004 by Ralf Heim at the [[Free University of Berlin]]. It acts as a potent [[partial agonist]] for the [[5HT2A receptor|5HT<sub>2A</sub>]] [[Receptor (biochemistry)|receptor]].<ref name=ralfheim>{{cite web |author =Ralf Heim |title=Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. |url=http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 |publisher=diss.fu-berlin.de |date=February 28, 2010 |language=German |accessdate=2013-05-10}}</ref><ref>Maria Silva PhD. [http://epub.uni-regensburg.de/12119/ Theoretical study of the interaction of agonists with the 5-HT2A receptor.] Universität Regensburg, 2009.</ref><ref name="pmid21088982">{{cite journal |vauthors=Silva ME, Heim R, Strasser A, Elz S, Dove S |title=Theoretical studies on the interaction of partial agonists with the 5-HT(2A) receptor |journal=Journal of Computer-aided Molecular Design |volume=25 |issue=1 |pages=51–66 |date=January 2011 |pmid=21088982 |doi=10.1007/s10822-010-9400-2 |url=}}</ref><ref>{{Cite journal | last1 = Hansen | first1 = M. | last2 = Phonekeo | first2 = K. | last3 = Paine | first3 = J. S. | last4 = Leth-Petersen | first4 = S. | last5 = Begtrup | first5 = M. | last6 = Bräuner-Osborne | first6 = H. | last7 = Kristensen | first7 = J. L. | doi = 10.1021/cn400216u | title = Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT<sub>2A/2C</sub> Agonists | journal = ACS Chemical Neuroscience | volume = 5 | issue = 3 | pages = 243–9  | year = 2014 | pmid = 24397362| pmc = 3963123
}}</ref> Anecdotal reports from users{{Citation needed|date=July 2012}} suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250–500&nbsp;[[µg]],{{Citation needed|date=July 2012}} making it a similar potency to other phenethylamine derived hallucinogens such as [[bromo-dragonfly]]. Duration of effects lasts about 12–16 hours.{{Citation needed|date=July 2012}}

The carbon-11 labeled version of this compound ([<sup>11</sup>C]Cimbi-36) was synthesized and validated as a [[radioactive tracer]] for positron emission tomography (PET) in Copenhagen.<ref>Hansen, M. (2011). [http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain.] PhD Thesis, University of Copenhagen.</ref><ref>{{Cite journal |doi= 10.1007/s00259-010-1686-8 |last= Ettrup |first= A. | last2= Hansen | first2= M. |last3= Santini | first3= M. A. |last4= Paine | first4= J. |last5= Gillings | first5= N. |last6= Palner | first6= M. |last7= Lehel | first7= S. |last8= Herth | first8= M. M. |last9= Madsen | first9= J. | first10= J. | last10= Kristensen |displayauthors=9 | first11= M. | last11 = Begtrup | first12= G. M. | last12 = Knudsen | title = Radiosynthesis and ''in vivo'' evaluation of a series of substituted <sup>11</sup>C-phenethylamines as 5-HT<sub>2A</sub> agonist PET tracers |journal= European Journal of Nuclear Medicine and Molecular Imaging |volume= 38 |issue= 4 |pages= 681–93 |year= 2010 |pmid= 21174090 }}
</ref><ref>{{Cite journal | last1 = Ettrup | first1 = A. | last2 = Holm | first2 = S. R. | last3 = Hansen | first3 = M. | last4 = Wasim | first4 = M. | last5 = Santini | first5 = M. A. | last6 = Palner | first6 = M. | last7 = Madsen | first7 = J. | last8 = Svarer | first8 = C. | last9 = Kristensen | first9 = J. L. | last10 = Knudsen | first10 = G. M. | title = Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand \11C]Cimbi-36 | doi = 10.1007/s11307-012-0609-4 | journal = Molecular Imaging and Biology | volume = 15 | issue = 4 | pages = 376–383 | year = 2013 | pmid =  23306971| pmc = }}</ref> As a 5-HT<sub>2A</sub> receptor agonist PET radioligand, [<sup>11</sup>C]Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, [<sup>11</sup>C]Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels [[in vivo]]. [<sup>11</sup>C]Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans.<ref>{{cite web|url=http://www.cimbi.dk/images/stories/files/The_full_Cimbi36_story.pdf |title=From molecule to man: The full CIMBI-36 story |work=cimbi.dk |date= |accessdate=2014-01-10 |format=PDF }}</ref><ref>{{cite web|url=http://www.imanova.co.uk/news-and-publications/imanova-news/entry/imanova-announces-the-launch-of-a-new-imaging-biomarker-to-investigate-the-serotonin-system-in-psychiatric-illness.html |title=Imanova announces the launch of a new imaging biomarker to investigate the serotonin system in psychiatric illness |work=imanova.co.uk |date= |accessdate=2015-04-09 }}</ref>

== Toxicity and harm potential ==

25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose is only 1/300th the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans.<ref>[http://bitnest.ca/external.php?id=%257DbxUgX%255DCY%2504%2505wzx%2519%2505VYL%2502RI%257E%2560d Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand &#91;11C&#93;Cimbi-36]</ref>  One case has been reported on where 25B-NBOMe was identified as the cause of death for a 17-year-old boy.<ref>{{cite news |title=Designer Drug Identified As Cause Of Plano Teen’s Death |date=February 19, 2015 |first=Gabriel |last=Roxas |url=http://dfw.cbslocal.com/2015/02/19/designer-drug-identified-as-cause-of-plano-teens-death/|newspaper=CBS 11 News |access-date=2015-02-22}}</ref>  Several deaths have been attributed to its close analogue [[25I-NBOMe]].

===Analogues and derivatives===
{{2C-B analogues and derivatives}}

== Legal status ==

===Canada===
As of October 31, 2016; 25B-NBOMe is a controlled substance (Schedule III) in Canada.<ref>http://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors72-eng.php</ref>

===Russia===
Banned as a narcotic drug since May 5, 2015.<ref>http://base.garant.ru/12112176/</ref>

===Sweden===
In Sweden, the [[Riksdag]] added 25B-NBOMe to schedule I (''"substances, plant materials and fungi which normally do not have medical use"'') as narcotics in Sweden as of August 1, 2013,  published by [[Medical Products Agency (Sweden)|''Medical Products Agency'']] in their regulation '''LVFS 2013:15''' listed as '''25B-NBOMe 2-(4-bromo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin'''.<ref>{{cite web|url=http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf |title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter  (LVFS 2011:10) om förteckningar över narkotika; |work=lakemedelsverket.se |date= |accessdate=2013-10-04 |format=PDF |language=swedish}}</ref>

===United Kingdom===
{{N-benzylphenethylamine-Legality-United Kingdom}}

===United States===
In November 2013, the U.S. Drug Enforcement Administration placed 25B-NBOMe (along with [[25I-NBOMe]] and [[25C-NBOMe]]) temporarily in Schedule I of the Controlled Substances Act, making it an illicit drug for two years.<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref>  In November 2015, the temporary scheduling was extended for another year.<ref name=pmid26567439>{{cite journal | journal = Fed Regist. | date = 2015 | volume = 80 | issue = 219 | pages = 70657–9 | title = Schedules of Controlled Substances: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I. Final order | author = Drug Enforcement Administration | pmid= 26567439}}</ref>

===China===
As of October 2015 25B-NBOMe is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

===Czech Republic===
25B-NBOMe is banned in the Czech Republic.<ref>{{cite web | url=http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | title=Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení  vlády č. 463/2013 Sb.) | publisher=Ministerstvo zdravotnictví | language=Czech}}</ref>

==References==
{{reflist}}

{{Hallucinogenic phenethylamines}}

[[Category:2C (psychedelics)]]
[[Category:Designer drugs]]
[[Category:Bromoarenes]]
[[Category:Phenol ethers]]
[[Category:PET radiotracers]]